Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Eurofins Scientific SE    ERF   FR0000038259

EUROFINS SCIENTIFIC SE

(ERF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eurofins : Technologies Launches Total Antibody (IgG, IgA and IgM) Detection ELISA Assays to Aid the Rapid Identification of Persons Who Have Been Exposed to SARS-CoV-2 (COVID-19)

share with twitter share with LinkedIn share with facebook
06/03/2020 | 01:11pm EDT

Regulatory News:

Eurofins Technologies (Paris:ERF) announces the launch of a serology-based total antibody (IgG, IgA and IgM) detection ELISA assay for indirect diagnostic of past exposure to COVID-19. The development of the assay has been led by Eurofins Ingenasa, a Eurofins Technologies company involved in the development of diagnostic tests supporting the control of infectious diseases for over 35 years in veterinary and more recently in human diagnostics.

While molecular diagnostic techniques (PCR) are a direct indicator of the COVID-19 disease, serological tests determine whether a person has been exposed to the infection and has therefore developed antibodies to SARS-CoV-2.

The CE-IVD marked INgezim COVID 19 DR is a dual recognition enzyme-linked immunosorbent assay (ELISA) capable of detecting semi-quantitatively total SARS-CoV-2 virus N-protein-specific antibodies (IgG, IgM and IgA) in a single human serum or plasma sample. The assays use the SARS-CoV-2 nucleoprotein (N protein) as antigen for the detection of antibodies to SARS-CoV-2. The N protein is one of the most abundant early-onset proteins of the virus, as well as being highly immunogenic and therefore a good candidate antigen for the diagnosis of COVID-19.

The assay is capable of detecting any type of antibody specific to the SARS-CoV-2 N protein (IgA, IgG, IgM) without differentiating between them. However, this highly sensitive test is particularly recommended for the early detection of SARS-CoV-2-specific antibodies as it favours the detection of IgM due to its ability to capture more than one conjugated N-protein molecule.

Validation of the assay with a panel of 332 well characterized sera samples confirmed an analytical sensitivity of 100% from day 17 after symptoms onset (85% between days 7 and 16) and a specificity of 99.2%. No cross-reactivity with other respiratory coronaviruses (229E, NL63, OC43 and HKU1) was detected and no interferences have been found for antibodies for respiratory viruses such as Influenza or RSV.

The ELISA assays determine total antibodies in serum samples with an incubation time of 75 minutes with no requirement for sample pre-dilution. INgezim COVID 19 DR kits are compatible with various open-platform ELISA analysers.

According to experts, there is a large range of applications for serologic testing. Serology can be used to complement the PCR swab testing that detects the virus to help diagnose acute infections status and its evolution. It can help estimate the timing of infection. As knowledge develops about the immunity to potential reinfection of patients having previously contracted COVID-19 and recovered, antibodies testing may provide information about statistically reduced contagion risks of and from these persons. It could also help identify donors of plasma from recovered patients that can be transfused into COVID-19 patients as a potential treatment.

Eurofins Technologies companies NovaTec, VIROTECH and Gold Standard Diagnostics have previously launched serological tests for the individual determination of IgG, IgM and IgA antibodies in April 2020. Today’s announcement completes the Group’s offering for antibody testing by ELISA.

For more information on the assay, please visit the Eurofins Technologies webpage.

Notes for the editor:

About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods

Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.

Its R&D teams located at various sites around the world share their expertise in developing a wide range of innovative methods and applications with a focus on immunoassays and molecular testing. For further information, please visit the Eurofins Technologies website.

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
Latest news on EUROFINS SCIENTIFIC SE
07/01EUROFINS SCIENTIFIC : publishes method for early detection of asymptomatic SARS-..
BU
07/01EUROFINS TECHNOLOGIES : Launches Rapid Point-of-Care Testing Devices That Identi..
BU
06/18EUROFINS TECHNOLOGIES : Announces AOAC Performance Tested MethodsSM Status for S..
BU
06/03EUROFINS : Technologies Launches Total Antibody (IgG, IgA and IgM) Detection ELI..
BU
05/29EUROFINS LAUNCHES EUROFINS SAFER@WOR : A Comprehensive Suite of Risk-Based COVID..
BU
05/21EUROFINS SCIENTIFIC : Labs@Home™ Facilitates Outpatient Management of Kidn..
PR
05/19EUROFINS SCIENTIFIC : raises EUR 535m following a successful equity issuance
PU
05/18EUROFINS SCIENTIFIC : announces the issuance of c. 900,000 new shares via an acc..
PU
05/14EUROFINS SCIENTIFIC : Announces the Success of Its Tender Offers on Its Outstand..
BU
05/07France's Eurofins launches product to detect coronavirus
RE
More news
Financials
Sales 2020 5 015 M 5 683 M 5 683 M
Net income 2020 289 M 328 M 328 M
Net Debt 2020 2 868 M 3 250 M 3 250 M
P/E ratio 2020 37,3x
Yield 2020 0,67%
Capitalization 10 537 M 11 925 M 11 941 M
EV / Sales 2019
EV / Sales 2020 2,67x
Nbr of Employees 47 427
Free-Float 69,8%
Chart EUROFINS SCIENTIFIC SE
Duration : Period :
Eurofins Scientific SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EUROFINS SCIENTIFIC SE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 568,66 €
Last Close Price 563,80 €
Spread / Highest target 28,1%
Spread / Average Target 0,86%
Spread / Lowest Target -36,1%
EPS Revisions
Managers
NameTitle
Gilles J. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Andreas König Chief Information Officer
Yves-Loïc Martin Non-Executive Director
Valérie Hanote Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
EUROFINS SCIENTIFIC SE14.08%12 061
FISERV, INC.-16.28%64 813
GLOBAL PAYMENTS INC.-8.22%50 118
CINTAS CORPORATION0.33%28 091
OFFCN EDUCATION TECHNOLOGY CO., LTD.63.76%26 627
NEW ORIENTAL EDUCATION & TECHNOLOGY GROUP INC.13.52%21 806